SNAPC5

Summary

SNAPC5 (small nuclear RNA activating complex polypeptide 5, HGNC:15484) is a protein-coding gene on chromosome 15q22.31, encoding snRNA-activating protein complex subunit 5 (O75971). Part of the SNAPc complex required for the transcription of both RNA polymerase II and III small-nuclear RNA genes. It is a common-essential gene (DepMap: required in 98.8% of cancer cell lines).

This gene encodes a subunit of the small nuclear RNA (snRNA)-activating protein complex that plays a role in the transcription of snRNA genes. This complex binds to the promoters of snRNA genes transcribed by either RNA polymerase II or III and recruits other regulatory factors to activate snRNA gene transcription. The encoded protein may play a role in stabilizing this complex. A pseudogene of this gene has been identified on chromosome 6.

Source: NCBI Gene 10302 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 33 total
• Cancer dependency (DepMap): dependent in 98.8% of screened cell lines (common-essential)
• MANE Select transcript: NM_001329615

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15484
Approved symbol	SNAPC5
Name	small nuclear RNA activating complex polypeptide 5
Location	15q22.31
Locus type	gene with protein product
Status	Approved
Aliases	SNAP19
Ensembl gene	ENSG00000174446
Ensembl biotype	protein_coding
OMIM	605979
Entrez	10302

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 5 protein_coding, 3 nonsense_mediated_decay

ENST00000307979, ENST00000316634, ENST00000395589, ENST00000562411, ENST00000563480, ENST00000565465, ENST00000566658, ENST00000568875

RefSeq mRNA: 4 — MANE Select: NM_001329615 NM_001329613, NM_001329614, NM_001329615, NM_006049

CCDS: CCDS10217, CCDS86469

Canonical transcript exons

ENST00000316634 — 3 exons

Exon	Start	End
ENSE00001406569	66493468	66494552
ENSE00002214319	66497642	66497762
ENSE00003572321	66495330	66495419

Expression profiles

Bgee: expression breadth ubiquitous, 299 present calls, max score 96.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.4002 / max 204.9543, expressed in 1806 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
150594	18.8580	1806
150595	0.5422	296

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	96.96	gold quality
middle temporal gyrus	UBERON:0002771	95.81	gold quality
sperm	CL:0000019	95.48	gold quality
Brodmann (1909) area 23	UBERON:0013554	95.45	gold quality
palpebral conjunctiva	UBERON:0001812	95.44	gold quality
eye	UBERON:0000970	95.07	gold quality
gastrocnemius	UBERON:0001388	95.06	gold quality
muscle of leg	UBERON:0001383	94.76	gold quality
male germ cell	CL:0000015	94.61	gold quality
choroid plexus epithelium	UBERON:0003911	94.55	gold quality
vastus lateralis	UBERON:0001379	94.53	gold quality
muscle organ	UBERON:0001630	94.50	gold quality
skeletal muscle organ	UBERON:0014892	94.50	gold quality
gluteal muscle	UBERON:0002000	94.40	gold quality
prefrontal cortex	UBERON:0000451	94.35	gold quality
biceps brachii	UBERON:0001507	94.31	gold quality
corpus epididymis	UBERON:0004359	94.13	gold quality
quadriceps femoris	UBERON:0001377	94.12	gold quality
nucleus accumbens	UBERON:0001882	94.06	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.05	gold quality
parotid gland	UBERON:0001831	94.01	gold quality
right frontal lobe	UBERON:0002810	93.97	gold quality
hair follicle	UBERON:0002073	93.95	gold quality
amniotic fluid	UBERON:0000173	93.93	gold quality
deltoid	UBERON:0001476	93.92	gold quality
putamen	UBERON:0001874	93.80	gold quality
pigmented layer of retina	UBERON:0001782	93.78	gold quality
myocardium	UBERON:0002349	93.76	gold quality
retina	UBERON:0000966	93.75	gold quality
heart left ventricle	UBERON:0002084	93.75	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.69

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 98.8% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 1)

• Kaplan-Meir analysis of GSE7696 indicate that COL3A1 and SNAP91 correlated with survival. (PMID:27655637)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	snapc5	ENSDARG00000062476
mus_musculus	Snapc5	ENSMUSG00000032398
rattus_norvegicus	Snapc5	ENSRNOG00000010156

Protein

Protein identifiers

snRNA-activating protein complex subunit 5 — O75971 (reviewed: O75971)

Alternative names: Small nuclear RNA-activating complex polypeptide 5, snRNA-activating protein complex 19 kDa subunit

All UniProt accessions (3): O75971, H3BQA0, H3BSI3

UniProt curated annotations — full annotation on UniProt →

Function. Part of the SNAPc complex required for the transcription of both RNA polymerase II and III small-nuclear RNA genes. Binds to the proximal sequence element (PSE), a non-TATA-box basal promoter element common to these 2 types of genes. Recruits TBP and BRF2 to the U6 snRNA TATA box.

Subunit / interactions. Part of the SNAPc complex composed of 5 subunits: SNAPC1, SNAPC2, SNAPC3, SNAPC4 and SNAPC5. SNAPC5 interacts with SNAPC4.

Subcellular location. Nucleus.

Isoforms (2)

UniProt ID	Names	Canonical?
O75971-1	1	yes
O75971-2	2

RefSeq proteins (4): NP_001316542, NP_001316543, NP_001316544, NP_006040 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029138	SNAPC5	Family

Pfam: PF15497

UniProt features (10 total): compositionally biased region 2, mutagenesis site 2, chain 1, region of interest 1, modified residue 1, splice variant 1, helix 1, turn 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
7ZWD	ELECTRON MICROSCOPY	3
7ZX8	ELECTRON MICROSCOPY	3
7ZWC	ELECTRON MICROSCOPY	3.2
7ZX7	ELECTRON MICROSCOPY	3.4
7ZXE	ELECTRON MICROSCOPY	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75971-F1	76.78	0.41

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 85

Mutagenesis-validated functional residues (2):

Position	Phenotype
8	reduced snapc4 binding in both the presence or absence of snapc1.
18	minimal effect on snapc4 binding in the absence of snapc1. reduced snapc4 binding in the presence of snapc1.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-6807505	RNA polymerase II transcribes snRNA genes
R-HSA-749476	RNA Polymerase III Abortive And Retractive Initiation
R-HSA-76071	RNA Polymerase III Transcription Initiation From Type 3 Promoter
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74158	RNA Polymerase III Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-76046	RNA Polymerase III Transcription Initiation

MSigDB gene sets: 150 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION_FROM_TYPE_3_PROMOTER, BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, GOBP_TRANSCRIPTION_BY_RNA_POLYMERASE_III, MODULE_308, GOBP_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, CREB_Q2_01, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, SCHLOSSER_SERUM_RESPONSE_DN, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, MODULE_124, NUYTTEN_EZH2_TARGETS_DN, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, MARSON_BOUND_BY_E2F4_UNSTIMULATED, BLALOCK_ALZHEIMERS_DISEASE_DN

GO Biological Process (4): transcription initiation at RNA polymerase III promoter (GO:0006384), snRNA transcription by RNA polymerase II (GO:0042795), snRNA transcription by RNA polymerase III (GO:0042796), transcription by RNA polymerase II (GO:0006366)

GO Molecular Function (3): RNA polymerase III general transcription initiation factor activity (GO:0000995), RNA polymerase II general transcription initiation factor activity (GO:0016251), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), nuclear body (GO:0016604)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
RNA Polymerase III Transcription	2
Gene expression (Transcription)	2
RNA Polymerase II Transcription	1
RNA Polymerase III Transcription Initiation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase III	3
transcription by RNA polymerase II	2
snRNA transcription	2
general transcription initiation factor activity	2
nuclear lumen	2
intracellular membraneless organelle	2
DNA-templated transcription initiation	1
DNA-templated transcription	1
binding	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
nucleoplasm	1

Protein interactions and networks

STRING

324 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SNAPC5	SNAPC4	Q5SXM2	989
SNAPC5	SNAPC2	Q13487	988
SNAPC5	SNAPC1	Q16533	984
SNAPC5	SNAPC3	Q92966	983
SNAPC5	TBP	P20226	558
SNAPC5	LCTL	Q6UWM7	518
SNAPC5	PASK	Q96RG2	471
SNAPC5	BRF2	Q9HAW0	447
SNAPC5	POLR3D	P05423	445
SNAPC5	TEX261	Q6UWH6	436
SNAPC5	TM2D2	Q9BX73	415
SNAPC5	DTYMK	P23919	412
SNAPC5	CAPN15	O75808	407
SNAPC5	RRP9	O43818	393
SNAPC5	TMEM178A	Q8NBL3	393

IntAct

54 interactions, top by confidence:

A	B	Type	Score
SNAPC5	NMI	psi-mi:“MI:0915”(physical association)	0.740
NMI	SNAPC5	psi-mi:“MI:0915”(physical association)	0.740
SNAPC1	SNAPC5	psi-mi:“MI:0914”(association)	0.740
SNAPC1	SNAPC5	psi-mi:“MI:0915”(physical association)	0.740
SNAPC4	SNAPC5	psi-mi:“MI:0914”(association)	0.620
SNAPC4	SNAPC5	psi-mi:“MI:0915”(physical association)	0.620
ZNRD2	SNAPC5	psi-mi:“MI:0915”(physical association)	0.560
DDIT3	SNAPC5	psi-mi:“MI:0915”(physical association)	0.560
SNAPC5	NUP62	psi-mi:“MI:0915”(physical association)	0.560
SNAPC5	AMOT	psi-mi:“MI:0915”(physical association)	0.560
NUDT10	SNAPC5	psi-mi:“MI:0915”(physical association)	0.560
NOL4	SNAPC5	psi-mi:“MI:0915”(physical association)	0.560
CYTH4	SNAPC5	psi-mi:“MI:0915”(physical association)	0.560
SNAPC5	NDEL1	psi-mi:“MI:0915”(physical association)	0.560
SNAPC5	ZNRD2	psi-mi:“MI:0915”(physical association)	0.560
NUP62	SNAPC5	psi-mi:“MI:0915”(physical association)	0.560
AMOT	SNAPC5	psi-mi:“MI:0915”(physical association)	0.560
SNAPC5	NUDT10	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (60): SNAPC5 (Two-hybrid), SNAPC5 (Two-hybrid), SNAPC5 (Two-hybrid), SSSCA1 (Two-hybrid), NUP62 (Two-hybrid), CYTH4 (Two-hybrid), NDEL1 (Two-hybrid), AMOT (Two-hybrid), NUDT10 (Two-hybrid), SNAPC5 (Affinity Capture-MS), BATF (Two-hybrid), BRCC3 (Two-hybrid), SNAPC5 (Two-hybrid), SNAPC5 (Two-hybrid), NMI (Two-hybrid)

ESM2 similar proteins: A0JNH9, A1L162, A2VCV0, A6QQ66, B3NLX1, B4P6W7, B8QB46, O75496, O75971, O88513, P32447, P51860, P53911, P85107, Q03563, Q04996, Q2T9W9, Q3UYG8, Q4VA55, Q5H9M0, Q5RD97, Q5W0B1, Q5ZMS4, Q60524, Q641E3, Q65Z40, Q66H73, Q6AWX6, Q6BKL0, Q6DFV7, Q6KAQ7, Q6PG04, Q6TXG9, Q794H2, Q7X9V2, Q7Z5K2, Q8INT5, Q8IW19, Q8IYH5, Q8L7S0

Diamond homologs: O75971, Q29S17, Q8R2K7

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SNAPC5	“form complex”	SNAPC	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	23
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

614 predictions. Top by Δscore:

Variant	Effect	Δscore
15:66490497:TGCA:T	acceptor_loss	1.0000
15:66490498:GCAG:G	acceptor_loss	1.0000
15:66490500:A:AT	acceptor_loss	1.0000
15:66490501:GGTTC:G	acceptor_gain	1.0000
15:66494432:T:TA	donor_gain	1.0000
15:66494455:T:TA	donor_gain	1.0000
15:66490494:A:AG	acceptor_gain	0.9900
15:66490495:C:G	acceptor_gain	0.9900
15:66490496:A:AG	acceptor_gain	0.9900
15:66490496:AT:A	acceptor_gain	0.9900
15:66490497:T:G	acceptor_gain	0.9900
15:66490500:A:AG	acceptor_gain	0.9900
15:66490500:AG:A	acceptor_gain	0.9900
15:66490501:G:GG	acceptor_gain	0.9900
15:66490501:GG:G	acceptor_gain	0.9900
15:66490501:GGTT:G	acceptor_gain	0.9900
15:66494413:ACCAG:A	donor_gain	0.9900
15:66494414:CCAGC:C	donor_gain	0.9900
15:66494461:T:TA	donor_gain	0.9900
15:66490137:C:CG	donor_gain	0.9800
15:66490144:A:AG	donor_gain	0.9800
15:66490494:ACAT:A	acceptor_gain	0.9800
15:66490497:T:TA	acceptor_gain	0.9800
15:66490501:GGT:G	acceptor_gain	0.9800
15:66494426:T:A	donor_gain	0.9800
15:66497637:GTCA:G	donor_loss	0.9800
15:66497638:TCA:T	donor_loss	0.9800
15:66497639:CA:C	donor_loss	0.9800
15:66497640:A:AC	donor_loss	0.9800
15:66497641:C:CT	donor_loss	0.9800

AlphaMissense

636 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:66497709:A:G	L8P	0.998
15:66495403:A:G	L36P	0.995
15:66497649:C:G	R28P	0.995
15:66497655:A:G	L26P	0.995
15:66497667:A:G	L22P	0.995
15:66497646:A:G	L29P	0.994
15:66497646:A:T	L29H	0.993
15:66497718:A:G	L5P	0.993
15:66495403:A:T	L36H	0.992
15:66497642:C:A	K30N	0.991
15:66497642:C:G	K30N	0.991
15:66497650:G:T	R28S	0.991
15:66497679:A:G	L18S	0.989
15:66497706:C:G	R9P	0.988
15:66497723:G:C	S3R	0.987
15:66497723:G:T	S3R	0.987
15:66497725:T:G	S3R	0.987
15:66495415:T:A	E32V	0.986
15:66497688:A:T	L15Q	0.986
15:66497675:C:A	K19N	0.985
15:66497675:C:G	K19N	0.985
15:66497709:A:T	L8Q	0.985
15:66497674:C:G	A20P	0.984
15:66497685:A:G	L16P	0.984
15:66497671:C:G	A21P	0.982
15:66497688:A:G	L15P	0.982
15:66494521:A:G	I71T	0.981
15:66497667:A:T	L22Q	0.981
15:66495407:C:G	A35P	0.980
15:66497718:A:T	L5H	0.980

dbSNP variants (sampled 300 via entrez): RS1000114741 (15:66498688 C>G,T), RS1000225167 (15:66495960 C>A,T), RS1000464745 (15:66493807 G>T), RS1000575684 (15:66496334 A>G), RS1000615099 (15:66497138 A>G), RS1000964707 (15:66497350 T>C), RS1001413604 (15:66492308 T>A), RS1001567249 (15:66497872 T>C,G), RS1001671524 (15:66498952 G>C), RS1002000334 (15:66498027 A>C), RS1002207676 (15:66498755 G>A,C,T), RS1002237721 (15:66498314 G>C,T), RS1002336616 (15:66492556 A>C,T), RS1002462355 (15:66495511 T>C), RS1002599699 (15:66495278 G>A,C)

Disease associations

OMIM: gene MIM:605979 | disease phenotypes: MIM:155950, MIM:615279

GenCC curated gene-disease

Mondo (4): melorheostosis (MONDO:0007970), cardiofaciocutaneous syndrome 3 (MONDO:0014113), RASopathy (MONDO:0021060), long QT syndrome (MONDO:0002442)

Orphanet (3): Cardiofaciocutaneous syndrome (Orphanet:1340), Melorheostosis (Orphanet:2485), RASopathy (Orphanet:536391)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547
D008557	Melorheostosis	C05.116.099.708.702.593

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
trichostatin A	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
pentanal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
bisphenol S	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Dexamethasone	increases expression, affects cotreatment	1
Indomethacin	affects cotreatment, increases expression	1
Naled	affects expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Silicon Dioxide	decreases methylation	1
Smoke	decreases expression	1
Taurine	increases expression	1
Valproic Acid	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Cadmium Chloride	increases expression	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

77 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT00076830	Not specified	COMPLETED	Evaluation and Treatment of Patients With Connective Tissue Disease
NCT07521150	Not specified	NOT_YET_RECRUITING	Physiotherapy and Rehabilitation in Melorheostosis: A Case Report
NCT04888936	Not specified	RECRUITING	Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
NCT05761314	Not specified	RECRUITING	Solid Tumors in RASopathies
NCT06331117	Not specified	UNKNOWN	Effect of RAS/MAPK Pathway Hyperactivation on Growth’ and Bone’ Profile of the RASopathies
NCT06355622	Not specified	UNKNOWN	Prevalence and Characterization of Pain in RASopathies
NCT06489067	Not specified	RECRUITING	Study of the Thyroid Function and Echostructural Morphology in Patients Affected With Rasopathies (ECORAS2023)
NCT06776380	Not specified	RECRUITING	Pubertal Development in Patients with RASopathies
NCT07005297	Not specified	NOT_YET_RECRUITING	Clinical Genetics Branch Eligibility Screening Survey
NCT07344480	Not specified	RECRUITING	Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)
NCT07464821	Not specified	RECRUITING	National Multicentre Study on Lipid Profile in Noonan Syndrome and Related Disorders: Trends by Age, Gender and Genotype
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes